» Articles » PMID: 31771313

Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study

Abstract

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is a major cause of morbidity and death in IPF. However, sensitive predictive factors of AE-IPF have not been well-investigated. To investigate whether high-resolution computed tomographic (HRCT) abnormalities predict AE-IPF in independent ethnic cohorts, this study included 121 patients with IPF (54 German and 67 Japanese; mean age, 68.5 ± 7.6 years). Two radiologists independently visually assessed the presence and extent of lung abnormalities in each patient. Twenty-two (18.2%) patients experienced AE-IPF during the follow-up. The incidence of AE-IPF was significantly higher in the Japanese patients ( = 18, 26.9%) than in the German patients ( = 4, 7.3%, < 0.01). In the Kaplan-Meier analysis, patients with a larger extent of ground glass opacity (GGO), fibrosis, and traction bronchiectasis experienced an earlier onset of AE-IPF ( = 0.0033, 0.0088, and 0.049, respectively). In the multivariate analysis, a larger extent of GGO and fibrosis on HRCT were independent predictors of AE-IPF ( = 0.026 and 0.037, respectively). Additionally, Japanese ethnicity was independently associated with the incidence of AE-IPF after adjustment for HRCT findings ( = 0.0074). In conclusion, a larger extent of GGO and fibrosis on HRCT and Japanese ethnicity appear to be risk factors for AE-IPF.

Citing Articles

Identification of risk factors for acute exacerbation of idiopathic pulmonary fibrosis based on baseline high-resolution computed tomography: a prospective observational study.

Wang Z, Zhang Z, Zhu L, Hou J, Fu H, Yang X BMC Pulm Med. 2024; 24(1):352.

PMID: 39030536 PMC: 11264818. DOI: 10.1186/s12890-024-03172-w.


Novel 3D-based deep learning for classification of acute exacerbation of idiopathic pulmonary fibrosis using high-resolution CT.

Huang X, Si W, Ye X, Zhao Y, Gu H, Zhang M BMJ Open Respir Res. 2024; 11(1).

PMID: 38460976 PMC: 10928777. DOI: 10.1136/bmjresp-2023-002226.


A predictive model for acute exacerbation of idiopathic interstitial pneumonias.

Karayama M, Aoshima Y, Suzuki T, Mori K, Yoshizawa N, Ichikawa S Eur Respir J. 2023; 61(5).

PMID: 36822633 PMC: 10160800. DOI: 10.1183/13993003.01634-2022.


Effect of COVID-19 on Lungs: Focusing on Prospective Malignant Phenotypes.

Sadhukhan P, Ugurlu M, Hoque M Cancers (Basel). 2020; 12(12).

PMID: 33352869 PMC: 7766284. DOI: 10.3390/cancers12123822.


Spliceosome-associated protein 130: a novel biomarker for idiopathic pulmonary fibrosis.

Liu K, Liu D, Feng Y, Zhang H, Zeng D, Liu Q Ann Transl Med. 2020; 8(16):986.

PMID: 32953786 PMC: 7475450. DOI: 10.21037/atm-20-4404.


References
1.
Kim D, Park J, Park B, Lee J, Nicholson A, Colby T . Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006; 27(1):143-50. DOI: 10.1183/09031936.06.00114004. View

2.
Judge E, Fabre A, Adamali H, Egan J . Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Eur Respir J. 2011; 40(1):93-100. DOI: 10.1183/09031936.00115511. View

3.
Song J, Hong S, Lim C, Koh Y, Kim D . Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2010; 37(2):356-63. DOI: 10.1183/09031936.00159709. View

4.
Costabel U, Inoue Y, Richeldi L, Collard H, Tschoepe I, Stowasser S . Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. Am J Respir Crit Care Med. 2015; 193(2):178-85. DOI: 10.1164/rccm.201503-0562OC. View

5.
Peljto A, Selman M, Kim D, Murphy E, Tucker L, Pardo A . The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. Chest. 2014; 147(2):460-464. PMC: 4314820. DOI: 10.1378/chest.14-0867. View